Rhythm Pharmaceuticals has been approved by the FDA for IMCIVREE for the treatment of chronic obesity due to deficiency of proopio melanocortin, proprotein-convertase, and leptin receptor in adults and children over 6 years. Production and sales are scheduled to start in Q1 2021.